Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for...
AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vac...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will...
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and h...
Saint Herblain (France), April 14, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company today announced that...
To potentially include adolescents and antibody persistence up to two yearsSaint Herblain (France), November 26, 2024 – Valneva...
Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster a...
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical tria...
